Results 81 to 90 of about 68,714 (217)

Cutaneous mastocytosis: Two pediatric cases treated with topical pimecrolimus. [PDF]

open access: yes, 2010
Cutaneous mastocytosis is characterized by increased numbers of skin mast cells that release mediators causing pruritus, urticaria, and flushing. Most pediatric mastocytosis patients exhibit the pattern of urticaria pigmentosa, which typically appears ...
Azevedo, R   +4 more
core   +1 more source

Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Yoshiaki Kobayashi   +9 more
wiley   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu   +9 more
wiley   +1 more source

Treatment Approaches for Diffuse Cutaneous Mastocytosis in Children: Literature Review and Actual Clinical Experience

open access: yesВопросы современной педиатрии
Background. Mastocytosis is a very rare disease with various manifestations, based on abnormal clonal proliferation of mast cells in organs and tissues, such as: skin, bone marrow, lymph nodes, liver, spleen, and gastrointestinal tract. The diagnosis can
Timur T. Valiev   +6 more
doaj   +1 more source

An Adult Patient with Systemic Mastocytosis and B-Acute Lymphoblastic Leukemia

open access: yesCase Reports in Medicine, 2014
Mastocytosis is a myeloproliferative neoplasm characterized by clonal expansion of abnormal mast cells, ranging from the cutaneous forms of the disease to mast cell leukemia.
Theodoros Iliakis   +13 more
doaj   +1 more source

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

open access: yesHaematologica, 2014
Chronic myeloid leukemia and systemic mastocytosis are myeloid neoplasms sharing a number of pathogenetic and clinical features. In both conditions, an aberrantly activated oncoprotein with tyrosine kinase activity, namely BCR-ABL1 in chronic myeloid ...
Siham Bibi   +9 more
doaj   +1 more source

Mast cell leukemia with prolonged survival on PKC412/midostaurin [PDF]

open access: yes, 2014
Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis. There are approximately 50 reported cases since 1950s. MCL is refractory to cytoreduction chemotherapy and the average survival is only six months. We report a MCL case in a
Frater, John L   +3 more
core   +1 more source

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]

open access: yes, 2015
Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core   +1 more source

Mast Cell Leukemia: Review of a Rare Disease and Case Report of Prolonged Survival after Allogeneic Stem Cell Transplant

open access: yesHuman Pathology: Case Reports, 2017
Mast cell leukemia is a rare and aggressive form of mastocytosis characterized by >20% mast cells found in the bone marrow aspirates of patients with signs of systemic mastocytosis-related organ damage.
James Bauer, MD, PhD   +2 more
doaj   +1 more source

Distinct Tryptase Gene Copy Number Variations Correlate With Tryptase Levels in a Population‐Based Cohort

open access: yes
Allergy, Volume 81, Issue 4, Page 1277-1280, April 2026.
Yannick Chantran   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy